 |
인쇄하기
취소
|
Yuhan Corporation acquires ‘Sovaldi’ & ‘Harvoni’ license worth of KRW 120 billion a year
In the official notice on the 5th, Yuhan Corporation announced it signed an exclusive sales agreement of ‘Sovaldi’ and ‘Harvoni,’ hepatitis C treatments, in Korea with U.S. Gilead.
Gilead’s ‘Sovaldi’ and ‘Harvoni’ sales in Korea were approximately KRW 120 billion in 2016.
Yuhan Corporation explained the last year’s sales of Sovaldi and Harvoni accounted for 9% of the total sales.
...Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.